Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

47.41 +0.23 (+0.49%)
Official Closing Price Updated: 6:30 PM EDT, Sep 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
78 79 Next >
Demand for Advanced Pancreatic Cancer Treatments at All Time High as Promising Options Come into Focus
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:GSK),(NASDAQ:AZN),(NASDAQ:GILD),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
Deal Dispatch: Biden Punts TikTok Ban To Trump, Plus Another Legacy Retailer Goes Bankrupt
Deal opportunities abound: KKR & Co.'s stake in Maya; DuPont's electronics business; Ingevity's North Charleston site; and S&W Seed Company. 
Via Benzinga
Topics Government
Decoding Bristol-Myers Squibb's Options Activity: What's the Big Picture?
 
Via Benzinga
This Unpopular Dividend Stock Is a Buy
Via The Motley Fool
Demand for Advanced Pancreatic Cancer Treatments at All Time High as Promising Options Come into Focus
From FN Media Group LLC
Via GlobeNewswire
Decoding Bristol-Myers Squibb's Options Activity: What's the Big Picture?
 
Via Benzinga
Peering Into Bristol-Myers Squibb's Recent Short Interest
 
Via Benzinga
2 High-Yield Dividend Stocks to Buy Early in 2025
Via The Motley Fool
Popular Ozempic, Wegovy Selected For Next Round Of Medicare Drug Price Negotiations
HHS adds 15 drugs to Medicare Part D price negotiations, targeting cost reductions under the Inflation Reduction Act. New prices aim to save billions by 2027. 
Via Benzinga
Topics Economy
Like Bristol-Myers Squibb And AbbVie, Johnson & Johnson Seeks To Bolster Neuropsychiatric Portfolio With $15 Billion Deal
Johnson & Johnson's $14.6 billion acquisition of Intra-Cellular Therapies boosts its CNS portfolio with Caplyta and a promising clinical-stage pipeline. 
Via Benzinga
ArsenalBio and Bristol Myers Squibb Achieve Milestone for AB-4000 Series as Part of Ongoing Multi-Program Collaboration to Advance Next-Generation T Cell Therapies for Solid Tumors
From Arsenal Biosciences
Via GlobeNewswire
Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference
JP Morgan highlights mixed sentiment for U.S. large-cap biopharma stocks as advancements in obesity drugs and key product launches shape 2025 outlook. 
Via Benzinga
Bristol Myers Squibb Stock Earns 83 RS Rating
On Thursday, Bristol Myers Squibb stock got a positive adjustment to its Relative Strength (RS) Rating, from 80 to 83. 
Via Investor's Business Daily
Alger Launches Russell Innovation ETF To Capitalize On Emerging Innovators
Alger launched its INVN ETF, with holdings including BioMarin, Teradata, and Bristol-Myers Squibb. 
Via Benzinga
Topics ETFs
Salesforce To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Wednesday
 
Via Benzinga
3 High-Yield Dividend Stocks to Buy Now and Hold at Least a Decade
Via The Motley Fool
Deal Dispatch: Vera Bradley Is A Mixed Bag, Modell's Ex-CEO Explores Party City
Vera Bradley faces shareholder pressure for underperformance, while acquisitions and restructurings define this week's deal landscape. 
Via Benzinga
Bristol Myers Squibb to Present at J.P. Morgan’s 43rd Annual Healthcare Conference
From Bristol Myers Squibb
Via Business Wire
U.S. Food and Drug Administration Approves Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo® (nivolumab) Indications1,2
From Bristol Myers Squibb
Via Business Wire
Exploring BRISTOL-MYERS SQUIBB CO's Technical Signals and Breakout Potential.
Investors are keeping a close eye on BRISTOL-MYERS SQUIBB CO (NYSE:BMY) as it boasts an impressive technical rating of 7 out of 10, signaling a possible breakout. 
Via Chartmill
Schwab US Dividend Equity ETF Reverses In December: What's Going On?
The Schwab US Dividend Equity ETF has given back more than half of its one-year gains in the last month, with the ETF falling more than 7% in December. Here's a look at what may be plaguing the fund: 
Via Benzinga
Topics ETFs
Bristol Myers Squibb Announces Positive Topline Results from Two Pivotal Phase 3 Trials Evaluating Sotyktu (deucravacitinib) in Adults with Psoriatic Arthritis
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer
From Bristol Myers Squibb
Via Business Wire
Got $500? This Top Dividend ETF Is a Great Buy After Its Recent Sell-Off.
Via The Motley Fool
Topics ETFs
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
JP Morgan highlights 2025 growth prospects for biopharma, animal health, and specialty pharma stocks. Key picks include Eli Lilly, Zoetis, and Bristol-Myers Squibb. 
Via Benzinga
Wall Street's Top 10 Stock Calls This Week - Saturday, Dec. 21
What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of Dec. 16-20, 2024. 
Via Talk Markets
Topics Stocks / Equities
Want Decades of Passive Income? 3 Stocks to Buy Right Now
Passive income requires solid companies and a solid underlying industry. Here are some top names that fit both bills. 
Via The Motley Fool
Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services
U.S. healthcare spending grew 7.5% to $4.9 trillion in 2023, with hospital care and prescription drugs driving costs. Private insurance accounted for 30% of total spending. 
Via Benzinga
3 High-Yielding Dividend Stocks That Retirees Can Rely On for Recurring Income
Via The Motley Fool
Bristol Myers Squibb to Report Results for Fourth Quarter 2024 on February 6, 2025
From Bristol Myers Squibb
Via Business Wire
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
78 79 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.